Cosmo Pharmaceuticals N.V. (CMOPF)

USD 66.93

(0.0%)

Revenue Summary of Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V.'s latest annual revenue in 2023 was 92.78 Million EUR , up 0.72% from previous year.
Cosmo Pharmaceuticals N.V.'s latest quarterly revenue in 2024 Q1 was 73.5 Million USD , up 177.36% from previous quarter.
Cosmo Pharmaceuticals N.V. reported a annual revenue of 110.81 Million USD in annual revenue 2022, up 43.76% from previous year.
Cosmo Pharmaceuticals N.V. reported a annual revenue of 77.07 Million USD in annual revenue 2021, up 4.48% from previous year.
Cosmo Pharmaceuticals N.V. reported a quarterly revenue of 73.5 Million USD for 2024 Q1, up 177.36% from previous quarter.
Cosmo Pharmaceuticals N.V. reported a quarterly revenue of 48.05 Million USD for 2023 Q2, up 102.92% from previous quarter.

Annual Revenue Chart of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Historical Annual Revenue of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Year	Revenue	Revenue Growth
2023	92.78 Million EUR	0.72%
2022	110.81 Million USD	43.76%
2021	77.07 Million USD	4.48%
2020	73.77 Million USD	2.78%
2019	71.78 Million USD	-6.59%
2018	76.85 Million EUR	0.32%
2017	76.6 Million EUR	5.58%
2016	72.55 Million EUR	12.23%
2015	64.64 Million EUR	-18.78%
2014	79.59 Million EUR	41.2%
2013	56.36 Million EUR	-5.32%
2012	59.53 Million EUR	77.67%
2011	33.5 Million EUR	4.55%
2010	32.05 Million EUR	20.1%
2009	26.68 Million EUR	-21.91%
2008	34.17 Million EUR	56.04%
2007	21.9 Million EUR	44.48%
2006	15.15 Million EUR	-2.24%
2005	15.5 Million EUR	40.58%
2004	11.03 Million EUR	0.0%

Year	Revenue	Revenue Growth
2024 Q2	72.97 Million USD	0.0%
2024 Q1	73.5 Million USD	177.36%
2023 Q2	48.05 Million USD	102.92%
2023 FY	111.61 Million USD	0.72%
2023 Q4	55.86 Million USD	115.18%
2023 Q3	25.96 Million USD	-45.97%
2023 Q1	23.67 Million USD	-63.05%
2022 FY	110.81 Million USD	43.76%
2022 Q4	64.08 Million USD	115.9%
2022 Q3	29.68 Million USD	-33.73%
2022 Q2	44.79 Million USD	0.0%
2021 FY	77.07 Million USD	4.48%
2021 Q4	42.9 Million USD	0.0%
2021 Q2	33.65 Million USD	0.0%
2020 Q2	29.06 Million USD	0.0%
2020 FY	73.77 Million USD	2.78%
2020 Q4	42.69 Million USD	0.0%
2019 Q4	46.39 Million USD	0.0%
2019 FY	71.78 Million USD	-6.59%
2019 Q2	24.91 Million USD	0.0%
2018 FY	76.85 Million EUR	0.32%
2017 FY	76.6 Million EUR	5.58%
2016 FY	72.55 Million EUR	12.23%
2015 FY	64.64 Million EUR	-18.78%
2014 FY	79.59 Million EUR	41.2%
2013 FY	56.36 Million EUR	-5.32%
2012 FY	59.53 Million EUR	77.67%
2011 FY	33.5 Million EUR	4.55%
2010 FY	32.05 Million EUR	20.1%
2009 FY	26.68 Million EUR	-21.91%
2008 FY	34.17 Million EUR	56.04%
2007 FY	21.9 Million EUR	44.48%
2006 FY	15.15 Million EUR	-2.24%
2005 FY	15.5 Million EUR	40.58%
2004 FY	11.03 Million EUR	0.0%

Peer Revenue Comparison of Cosmo Pharmaceuticals N.V.

Name	Revenue	Revenue Difference
AstraZeneca PLC	46.91 Billion USD	99.802%
Bristol-Myers Squibb Company PFD CONV 2	45 Billion USD	99.794%
CSPC Pharmaceutical Group Limited	31.45 Billion USD	99.705%
Clarus Therapeutics Holdings, Inc.	13.95 Million USD	-564.756%
Novartis AG	46.66 Billion USD	99.801%
PT Kalbe Farma Tbk.	1.97 Billion USD	95.312%